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Edited by Berend WieringaAbstract In adipogenesis, growth factors play a crucial role.
Using serum depleted condition, we studied the causal role of
endothelin-1 (ET-1) and epidermal growth factor (EGF), sepa-
rately or together, in adipocyte diﬀerentiation of 3T3-L1 cells.
ET-1 stimulation caused an anti-adipogenic response and this
eﬀect was potentiated upon treatment with EGF. Co-treatment
with EGF and ET-1 blocked the expression of C/EBPa and
PPARc, the adipogenic markers. The inhibition of adipogenesis
was preceded by a biphasic (early and late) attenuation of Akt
phosphorylation. We suggest that treatment with ET-1 and
EGF together induce a more potent anti-adipogenic response,
involving increased Erk1/2 phosphorylation and biphasic attenu-
ation of Akt phosphorylation.
 2006 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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factor; Obesity1. Introduction
Adipogenesis is a process wherein the preadipocytes diﬀeren-
tiate into adipocytes. This diﬀerentiation programme is
co-ordinated by several positive and negative adipogenic mole-
cules, including a variety of growth factors, cytokines and
hormones [1,2]. Growth factors trigger both pro- or anti-adipo-
genic transcription factors via activation of serine/threonine
kinase PKB/Akt and mitogen-activated protein kinase (MAPK)
signalling pathways. Insulin, an important pro-adipogenic ana-
bolic hormone, requires the activation of both Erk1/2 and Akt
for adipocyte diﬀerentiation [3,4]. However, the role of Erk1/2
in regulating adipocyte diﬀerentiation remains disputed [5]. On
the other hand, the contribution of Akt in adipocyte diﬀerenti-
ation is more established and dysfunction in this pathway has
been shown to inhibit adipogenesis [4,6,7].*Corresponding author. Address: Department of Molecular Biology,
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doi:10.1016/j.febslet.2006.09.032Earlier literature suggests that ET-1 and EGF play a physi-
ological role in the regulation of obesity [8–10]. The eﬀect of
ET-1, a 21 amino acid peptide with vasoconstrictor properties,
in adipocytes is well studied [11,12]. However, little informa-
tion exists on its role in adipogenesis [13,14]. The eﬀect of
EGF in adipogenesis is also ambiguous [15]. The existing liter-
ature frame EGF to be anti-adipogenic [10] however, in serum
free condition EGF does not promote an anti-adipogenic re-
sponse [16].
In the present work, we re-investigated the eﬀects of ET-1
and EGF separately or in combination in 3T3-L1 cell diﬀeren-
tiation. In addition, we analysed the contribution of the signal-
ling pathways, particularly Erk1/2 and Akt, in adipocyte
diﬀerentiation.2. Materials and methods
2.1. Materials and chemicals
Lysophosphatidic acid (LPA), ET-1, EGF and insulin were from
Sigma. Bisindolylmaleimide IX methanesulfonate (Ro 31-8220) was
bought from Alexis Biochemicals. Proliferation reagent WST-1 was
bought from Roche Applied Science. Antibodies used were rabbit
polyclonal anti-C/EBPa, anti-Erk2, anti-Akt and mouse monoclonal
anti-PPARc antibody (Santa Cruz Biotechnology), rabbit polyclonal
anti-phospho-p44/42 MAP Kinase and anti-phospho Akt (Ser473)
antibody (Cell Signaling Technology). Secondary horseradish peroxi-
dase-conjugated antibodies were goat anti-mouse antibody (Sigma)
and goat anti-rabbit antibody (Bio-Rad). All other chemicals were
from Sigma.2.2. Cell culture, induction of diﬀerentiation and oil red-o staining
Murine 3T3-L1 preadipocytes (fromATCC,Manassas, VA, USA) at
low passage were cultured in growth medium of Dulbecco’s modiﬁed
Eagle’s medium (DMEM) with low glucose (Invitrogen) and supple-
mented with 10% newborn calf serum (Invitrogen), 100 units/ml penicil-
lin, and 100 units/ml streptomycin (PAA laboratories GmbH, Austria).
Prior to induction of adipocyte diﬀerentiation, conﬂuent 3T3-L1 cells
were starved overnight in basal media comprising of DMEM supple-
mented with 1 lM biotin, 0.2 M ascorbic acid and 2 lg/ml transferrin.
Adipose conversion was induced (= day 0) with diﬀerentiation cocktail
MDI comprising of 1-methyl-3-isobutyl xanthine (MIBX; 0.5 mM),
dexamethasone (0.25 lM) and insulin (1 lg/ml) in basal media. Where
required ET-1 (100 nM), EGF (10 ng/ml) or FBS (10%) was added.
Four days later, cells were shifted to and maintained until the end of
the protocol (= day 8) in basal medium supplemented solely with
1 lg/ml insulin and stained for Oil Red-O, as described [7].
2.3. Glycerol 3-phosphate dehydrogenase (G3PDH) assay
To assess the degree of adipocyte diﬀerentiation, the activity of the
adipocyte marker enzyme G3PDH was measured on day 6 post-diﬀer-
entiation, as described previously [14].blished by Elsevier B.V. All rights reserved.
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Fig. 1. Eﬀect of ET-1 and EGF in adipogenesis. Conﬂuent 3T3-L1
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Total RNA was isolated using the RNeasy Mini Kit (Qiagen, Hil-
den, Germany) from undiﬀerentiated or day 4 post-diﬀerentiated
3T3-L1 cells following the manufacturer’s directions. RNA (1 lg)
was reversed transcribed using AMV reverse transcriptase (Roche,
Mannheim, Germany). PCR primers used for the detection of
PPAR-c2 and GAPDH mRNA were deduced from published se-
quences. PCR products were subjected to electrophoresis on a 2% aga-
rose gel and DNA was visualized by UV light after ethidium bromide
staining.
2.5. WST-1 analysis
Cell proliferation and cell viability was quantiﬁed using WST-1 re-
agent. Assay was performed as per the manufacturer’s instructions.
In brief, 3T3-L1 cells were seeded at 5000 cells per well in a 96-well
plate and grown in basal media with MDI in the absence or presence
of ET-1, EGF or combination of ET-1 and EGF for 3 days. WST-1
reagent was then added and incubation was carried at 37 C for 4 h.
The absorbance at 450 nm was measured with a microplate reader
(TECAN).
2.6. Stimulation of cells and immunoblotting
Cells were grown to conﬂuence and were either pre-treated with
inhibitor followed by agonist treatment or were directly treated with
agonists. Lysis was done on ice for various time periods as indicated
in the ﬁgure legends. For expression analysis of C/EBPa and PPARc,
RIPA lysis buﬀer was used. In other cases, lysis buﬀer comprising of
Triton X-100 was used [17]. Lysates were pre-cleared by centrifugation
at 13,000 rpm for 10 min at 4 C. Protein concentration was deter-
mined from supernatant aliquots using the BCA protein assay kit
(Pierce). Equal amounts of protein were subjected to gel electrophore-
sis followed by immunoblotting. Data shown are representative of
three independent experiments. Quantiﬁcation was done using Fuji
LAS1000 imaging system and AIDA Image Analyser v.4.03.
2.7. Statistical analysis
For statistical analysis, Student’s t test was used to compare data be-
tween two groups. Values are expressed as means ± S.D. of three inde-
pendent experiments. P < 0.05 was considered statistically signiﬁcant.preadipocytes were treated in accordance to the diﬀerentiation
protocol, as mentioned in Section 2. (A) G3PDH activity was
measured after 6 days post-diﬀerentiation. (B) Oil Red-O staining
was performed after 8 days post-diﬀerentiation. Each bar represents
means ± S.D. *P < 0.05 vs. MDI only treatment; P < .0.05 vs. ET-1
plus MDI treatment.3. Results
3.1. Eﬀect of ET-1 and EGF in adipogenesis
Glycerophosphate dehydrogenase (G3PDH) is a marker of
adipocytes and its activity increases upon diﬀerentiation.
Starved 3T3-L1 preadipocytes treated with diﬀerentiation
cocktail MDI alone or along with 10% FBS or EGF induced
high G3PDH activity (Fig. 1A). However, G3PDH activity
was signiﬁcantly reduced on treatment with ET-1 (74 ± 3%
vs. MDI alone) and a further reduction in G3PDH activity
was observed when EGF was co-treated with ET-1 (78 ± 13%
vs. ET-1 alone). To further validate the ET-1-induced inhibi-
tion of adipogenesis, Oil Red-O staining was performed to visu-
alise triacylglycerol levels. Well stained adipocytes were visible
upon treatment with FBS or EGF in the presence of MDI
(Fig. 1B). However, treatment with ET-1 caused a decrease in
Oil Red-O staining and when ET-1 was applied together with
EGF, the staining was hardly visible.
To further characterize the ET-1 induced anti-adipogenic ef-
fect and its potentiation in the presence of EGF, we monitored
the expression of crucial adipogenic transcription factors-C/
EBPa and PPARc. Expression of C/EBPa was detected from
day 2 post-diﬀerentiation in MDI treated cells (Fig. 2A) and
co-treatment with ET-1 and EGF blocked the expression of
C/EBPa from day 2 to day 4 even in the presence of MDI
(Fig. 2A; lanes 8, 12 and 16). Treatment with ET-1 alone
(Fig. 2A; lanes 6, 10 and 14) resulted in a marginal reductionin C/EBPa expression in comparison to EGF alone treated
cells (Fig. 2A; lanes 7, 11 and 15). Preadipocytes treated for
4 days with MDI alone or with EGF indicated normal expres-
sion of PPAR-c2 mRNA (Fig. 2B; lanes 3 and 5). However,
treatment with ET-1 alone or in combination with EGF
blocked the expression of PPAR-c2 mRNA (Fig. 2B; lanes 2
and 4). Similar result was also seen on analysis of PPARc pro-
tein levels (Fig. 2C), wherein ET-1 treatment (Fig. 2C; lanes 2
and 4) inhibited MDI induced PPARc expression. Protein
loading was checked by probing with anti-Erk2 antibody,
which recognises Erk 2 (p42) and, to a lesser extent , Erk 1
(p44).
3.2. ETA receptor and PKC mediated Erk1/2 phosphorylation by
ET-1
In 3T3-L1 preadipocytes, ET-1 via the ETA receptor could
phosphorylate both Erk1/2 and Akt (Fig. 3A). Pre-treatment
with BQ610, an ETA receptor antagonist, blocked Erk1/2
and Akt phosphorylation upon ET-1 stimulation (Fig. 3A;
lane 3). However, BQ610 did not block signalling via LPA
receptor (Fig. 3A; lane 5). Using a PKC inhibitor Ro 31-
8220, which inhibits conventional PKC isoforms, the Erk1/2
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Fig. 2. Expression analysis of adipogenic markers. Post conﬂuent 3T3-L1 preadipocytes were kept overnight in serum free conditions and then were
treated with MDI alone or with ligands. (A) Whole cell lysates from day 0 and from day 1 to day 4 were immunoblotted for C/EBPa expression. (C)
Lysates from day 4 were immunoblotted for PPARc expression. Reblot was done with anti-tubulin (A) and anti-Erk2 antibodies. (B) mRNA
expression of PPAR-c2 was monitored with RT-PCR using samples from day 4 post-diﬀerentiation. GAPDH mRNA expression was monitored as
loading control.
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stimulation (Fig. 3B; lanes 3 and 5). PMA, an activator of
PKC, induced Erk1/2 phosphorylation was blocked on pre-
treatment with Ro 31-8220 (lane 10). Pre-treatment with Ro
31-8220 had no eﬀect on Akt phosphorylation (data not
shown).
3.3. Erk1/2 phosphorylation and cell proliferation
Pro-adipogenic MDI and its each constituent phosphory-
lated Erk1/2 at 5 min but not at 30 min, post-stimulation
(Fig. 4A). However, in cells treated with ET-1 and EGF sepa-
rately or together in the presence of MDI, Erk1/2 phosphory-
lation was detected even at 30 min (Fig. 4B; lanes 2–4). At 1 h
and 2 h post-stimulation, ET-1 mediated Erk1/2 phosphoryla-
tion was weaker in comparison to EGF treatment (Fig. 4B;
1 h: lanes 6 vs. 7 and 2 h: lanes 10 vs. 11). Co-treatment with
ET-1 and EGF induced the strongest Erk1/2 phosphorylation
(Fig. 4B; lanes 4, 8 and 12). Data from cell proliferation assay
indicated that the maximum cell proliferation was attained on
co-treatment with ET-1 and EGF followed by treatment with
EGF and then with ET-1 treatment (Fig. 4C).
3.4. Attenuation of Akt phosphorylation
Amongst the components of pro-adipogenic MDI, only
insulin induced Akt phosphorylation even at 30 min post-stim-
ulation (Fig. 5A). We then investigated Akt phosphorylation
after treatment with ET-1 and EGF in the presence of MDI
in a time-dependent manner (Fig. 5B). Upon stimulation for
30 min, MDI alone or along with EGF induced a strong Akt
phosphorylation (Fig. 5B, lanes 3 and 5). Interestingly, at thistime point, treatment with ET-1 alone or together with EGF
attenuated MDI mediated Akt phosphorylation by 3-fold
(Fig. 5B, lanes 2 and 4). At 1 h post-stimulation, ET-1 medi-
ated attenuation of Akt phosphorylation was still present
(Fig. 5B, lanes 6 and 8). However, after 2 h post-stimulation,
the pattern of Akt phosphorylation became similar under all
treatment conditions (data not shown). To identify the precise
time window during which Akt phosphorylation was attenu-
ated, we co-treated cells with ET-1 and EGF in the presence
of MDI. The most signiﬁcant attenuation of Akt phosphoryla-
tion was seen from 10 min to 40 min, post-stimulation
(Fig. 5C). A recovery from attenuation was visible after
50 min. Similar trend in attenuation of Akt phosphorylation
was also seen on ET-1 treatment (data not shown). We also
monitored the Akt phosphorylation from day 1 to day 3
post-simulation (Fig. 5D). Treatment with ET-1 in the absence
(lanes 6 and 10) or presence of EGF (lanes 8 and 12) did not
induce Akt phosphorylation on day 2 and day 3 compared
to MDI treated cells or together with EGF.4. Discussion
In the present study, we demonstrate that ET-1 inhibits adi-
pogenesis and that this anti-adipogenic eﬀect is enhanced upon
co-treatment with EGF. However, EGF alone does not pro-
duce an anti-adipogenic eﬀect, as seen in our ﬁndings. The
result presented here indicate that ET-1 attenuates MDI
induced Akt phosphorylation in the early and late phase and
the occurrence of this attenuation may thus lower overall
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Fig. 3. ET-1 binds to ETA receptor to activate Erk1/2 via PKC. (A) Serum free 3T3-L1 preadipocytes were pre-treated with BQ610 (1 lM) or with
vehicle for 30 min and were then treated without or with ET-1 (100 nM) or LPA (10 lM) for 5 min. (B) Preadipocytes were pre-treated without or
with Ro 31-8220 (2.5 lM) for 30 min followed by treatment without or with ET-1, EGF or both for 5 min. PMA (1 lM) was added for 10 min. Total
cell lysates from both (A) and (B) were immunoblotted with phospho-Erk1/2 or phospho-Akt (Ser473) antibody and reblotted with Erk1/2 or Akt
antibody.
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phosphorylation causing increased cell proliferation contribute
to an anti-adipogenic response only when supported with an
attenuated Akt phosphorylation.
In this work, we selected ET-1 and EGF since they are both
known to be physiologically involved in adipose tissue devel-
opment and in regulating obesity [8,10]. The development of
cardiovascular disorders is accelerated by obesity and an in-
crease in ET-1 expression has been suggested to occur in the
cardiovascular system of obese animals [18].
In 3T3-L1 adipocytes, chronic stimulation (24 h) with ET-1
has been suggested to induce cellular insulin resistance by
desensitizing insulin signalling [12]. In this work using 3T3-
L1 preadipocytes, we observed that treatment with ET-1
desensitizes pro-adipogenic insulin signalling towards Akt,
since insulin was the only constituent in MDI that could phos-
phorylate Akt.Adipocyte diﬀerentiation could be blocked if the signalling
pathway, PI 3-kinase-PKB/Akt is disrupted, particularly at
Akt [4,7]. This was shown, in earlier works, by interfering
Akt signalling either by gene targeting or by using PI 3-kinase
inhibitors. In this context, our present work extends the under-
standing on the role of Akt since Akt signalling was analysed
in an endogenous set-up upon physiological mitogenic ligand
treatment. Our results here suggest that the ligands that cause
the early and late phase attenuation of Akt phosphorylation
also cause inhibition of adipogenesis.
The co-treatment with ET-1 and EGF caused an enhanced
anti-adipogenic eﬀect probably due to the repression of both
C/EBPa and PPARc expression. Rosen et al., have shown that
PPARc is the proximal eﬀector of adipogenesis since PPARc
can promote adipogenesis even in C/EBPa deﬁcient cells [19].
In our experiments, it is likely that ET-1 induces an anti-adipo-
genic eﬀect mainly through block in PPARc expression.
Fig. 4. Erk1/2 phosphorylation pattern. (A) Serum free 3T3-L1 preadipocytes were treated without or with MDI and its constituents for 5 and
30 min. (B) Preadipocytes were treated in absence or presence of MDI alone or together with ET-1, EGF or both for 30 min, 1 h and 2 h, respectively.
Whole cell lysates were immunoblotted with phospho-Erk1/2 antibody and then reblotted with Erk1/2 antibody. (C) Cell proliferation assay was
performed as mentioned in Section 2. Quantiﬁcation was done based on absorbance at 450 nm and is representative of means ± S.D. of three
independent experiments. *P < 0.05 and **P < 0.005 vs. ET-1 treated cells.
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activated protein kinase (MAPK), particularly Erk1/2 alongwith high cell proliferation favours inhibition of adipogenesis
[20]. If this holds true, then in our ﬁndings EGF should have
Fig. 5. Akt phosphorylation pattern. (A) Serum starved 3T3-L1 preadipocytes were treated without or with MDI and its constituents for 5 and
30 min. (B) Preadipocytes were treated in absence or presence of MDI alone or together with ET-1, EGF or both for 30 min and 1 h. (C)
Preadipocytes were co-treated with ET-1 and EGF in the presence of MDI in a time dependent manner. (D) Long-term treatment of preadipocytes in
the absence or presence of MDI or together with ET-1, EGF or both for days 1–3. Whole cell lysates were immunoblotted with phospho-speciﬁc Akt
(Ser473) and reblotted with Akt antibody. *P < 0.05 vs. MDI only treated cells (B and D) and *P < 0.05 vs. treatment at 50 min (C).
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this was not the case. As seen from our results on Erk1/2
phosphorylation and cell proliferation with ET-1 and EGF
co-treatment experiments, we believe that increased Erk1/2
phosphorylation may play a supportive role in inhibition of
adipogenesis only in conditions when the signalling via Akt
is disrupted.Inhibition of adipocyte diﬀerentiation may be seen as a res-
cue operation for tackling obesity as it prevents a further accu-
mulation of fat cells in adipose tissue. In this context, there
may be a possibility that the increase in ET-1 levels in obese
subjects [9] may provide a balancing trigger by blocking hyper-
plasia (increase in number of adipocytes). In contrast, adipo-
genesis is also a fundamental requirement in maintaining a
I. Bhattacharya, A. Ullrich / FEBS Letters 580 (2006) 5765–5771 5771healthy adipose tissue and restricting the formation of new adi-
pocytes may lead to the development of insulin resistant hyper-
trophied adipocytes [21]. Thus, ET-1 may exert both positive
and negative physiological eﬀects.
In conclusion, our data provides new information on the
anti-adipogenic action of ET-1. The desensitization of pro-adi-
pogenic MDI signalling by ET-1 results in a biphasic attenua-
tion of Akt phosphorylation. Whether the early transient
phase or the late phase attenuation of Akt phosphorylation
is responsible for the anti-adipogenic response, is a matter of
future investigation.
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